NF2 and neoplasm: For NF2-associated VS resistant to radiotherapy, targeted therapy such as bevacizumab has been shown to cause 30-60% tumor shrinkage and 20% hearing improvement35,36, although it has several side effects, such as apparent drug resistance and rebound tumor progression37.